APOE ε4 homozygous + 9p21 CAD risk allele
APOE ε4/ε4 combined with the 9p21 coronary artery disease risk allele.
You have two copies of the higher-risk APOE ε4 version plus a DNA change in a region called 9p21 that's linked to heart artery disease.
Two independent cardiovascular risk signals stacked. APOE ε4 homozygosity raises both Alzheimer's and cardiovascular risk; the 9p21 locus adds an independent CAD risk increment. Together these support paying particular attention to blood pressure, lipid management, and lifestyle.
You have two separate genetic nudges towards heart artery disease, working through different biology. Together they make blood pressure control, cholesterol management, and lifestyle choices unusually worthwhile for you.
What this means
These two signals act through different biology — APOE through lipid transport, the 9p21 region through cell-cycle control affecting vascular smooth muscle — so their effects on coronary artery disease risk are likely additive rather than redundant. None of this is destiny, but it shifts the prior meaningfully when planning cardiovascular prevention.
These two DNA changes affect heart artery disease in different ways. APOE helps move cholesterol around your blood; the 9p21 region affects how the muscle cells in your artery walls divide and repair themselves. Because they work through different biology, the two effects add up rather than overlap. This isn't destiny — neither alone or together guarantees anything — but it does shift the picture enough to take prevention seriously.
Caveats
- Lifestyle factors (blood pressure, lipids, smoking, exercise, diet) remain dominant.
- Each variant individually has only a modest effect; this is about the combination.
- Modern lipid-lowering therapy is highly effective at compensating for elevated genetic risk.